Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Chemoradiation in High-Risk Biliary Tract Cancer
NCT04333927Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2020
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in extrahepatic cholangiocarcinoma (eCCA) and gallbladder cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on NCT04333927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333927.